Mantovani, Alessandro

Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis

Mantovani, A., Csermely, A., Petracca, G., Beatrice, G., Corey, K. E., Simon, T. G., Byrne, C. D., & Targher, G. (2021) · The Lancet Gastroenterology & Hepatology

Liver Disease Diagnosis and TreatmentAlcohol Consumption and Health Effects

Cited by 674

Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals

Mantovani, A., Petracca, G., Beatrice, G., Tilg, H., Byrne, C. D., & Targher, G. (2021) · Gut

Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 481

Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis

Mantovani, A., Petracca, G., Beatrice, G., Csermely, A., Lonardo, A., Schattenberg, J. M., Tilg, H., Byrne, C. D., & Targher, G. (2022) · Gut

Liver Disease Diagnosis and TreatmentChronic Kidney Disease and Diabetes

Cited by 402

Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies

Mantovani, A., Petracca, G., Beatrice, G., Csermely, A., Tilg, H., Byrne, C. D., & Targher, G. (2022) · Gut

Liver Disease Diagnosis and TreatmentCancer Risks and Factors

Cited by 363

Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease

Anstee, Q. M., Mantovani, A., Tilg, H., & Targher, G. (2018) · Nature Reviews Gastroenterology & Hepatology

Liver Disease Diagnosis and TreatmentCardiovascular Function and Risk Factors

Cited by 310

Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials

Mantovani, A., Petracca, G., Beatrice, G., Csermely, A., Lonardo, A., & Targher, G. (2021) · Metabolites

Liver Disease Diagnosis and TreatmentDiabetes Treatment and Management

Cited by 299

Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: A systematic review

Mantovani, A., Byrne, C. D., & Targher, G. (2022) · The Lancet Gastroenterology & Hepatology

Liver Disease Diagnosis and TreatmentDiabetes Treatment and Management

Cited by 230

Epidemiology and pathophysiology of the association between NAFLD and metabolically healthy or metabolically unhealthy obesity

Lonardo, A., Mantovani, A., Lugari, S., & Targher, G. (2020) · Annals of Hepatology

Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 150

Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials

Mantovani, A., Byrne, C. D., Scorletti, E., Mantzoros, C. S., & Targher, G. (2020) · Diabetes & Metabolism

Liver Disease Diagnosis and TreatmentDiabetes Treatment and Management

Cited by 138

Non-alcoholic fatty liver disease and risk of new-onset heart failure: an updated meta-analysis of about 11 million individuals

Mantovani, A., Petracca, G., Csermely, A., Beatrice, G., Bonapace, S., Rossi, A., Tilg, H., Byrne, C. D., & Targher, G. (2023) · Gut

Liver Disease Diagnosis and TreatmentHeart Failure Treatment and Management

Cited by 128

Prognostic impact of diabetes on long-term survival outcomes in patients with heart failure: a meta-analysis

Dauriz, M., Mantovani, A., Bonapace, S., Verlato, G., Zoppini, G., Bonora, E., & Targher, G. (2017) · Diabetes Care

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 123

Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease

Targher, G., Mantovani, A., & Byrne, C. D. (2023) · The Lancet Gastroenterology & Hepatology

Liver Disease Diagnosis and TreatmentDiabetes Treatment and Management

Cited by 121

Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular disease in adult patients with type 1 diabetes

Mantovani, A., Mingolla, L., Rigolon, R., Pichiri, I., Cavalieri, V., Zoppini, G., Lippi, G., Bonora, E., & Targher, G. (2016) · International Journal of Cardiology

Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 82

Association between non-alcoholic fatty liver disease and bone turnover biomarkers in post-menopausal women with type 2 diabetes

Mantovani, A., Sani, E., Fassio, A., Colecchia, A., Viapiana, O., Gatti, D., Idolazzi, L., Rossini, M., Salvagno, G., Lippi, G., et al. (2019) · Diabetes & Metabolism

Bone health and osteoporosis researchLiver Disease Diagnosis and Treatment

Cited by 68

Coronavirus disease 2019 (COVID-19): We don’t leave women alone.

Mantovani, A., Dalbeni, A., & Beatrice, G. (2020) · International Journal of Public Health

Gender, Health, and Social InequalityGender Studies and Social Issues

Cited by 42